Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which
Toshiba America Medical Systems is planning a full-court pressat this month's Radiological Society of North America meeting.In an effort to secure a greater U.S. market share, the Japanesevendor is introducing a range of new products, many of which havebeen designed with input from U.S. clinicians, according to RaviSharma, vice president of marketing.
At the top of Toshiba's list of product introductions is Flexart,a new 0.5-tesla MRI scanner to be shown as a works-in-progress.Flexart uses a helium-only superconducting magnet designed forlow cryogen boil-off and low maintenance. The system is activelyshielded to reduce eddy currents and can be sited in a space assmall as 45 square meters, Sharma said.
"This has been developed mainly for community hospitalsand hospitals that are going to see high growth in the managed-careenvironment," he said.
Flexart will be priced at about $1 million and will be positionedas Toshiba's premium mid-field offering. The company will continueto sell MRT-50A, its existing mid-field product.
In CT, Toshiba will unveil Xpress/SX, an upgrade to the vendor'sXpress slip-ring CT scanner. The upgrade will add solid-statedetectors to Xpress, which enable faster helical scanning andimproved image quality, Sharma said.
The system is powered by a 48-kW generator with an output of400 mAs and runs a 3.5-million heat unit x-ray tube. Xpress/SXhas Food and Drug Administration marketing clearance. It willbe priced at about $1 million, Sharma said.
Other new product introductions include:
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.